Blood test clues could predict CAR-T success in myeloma
NCT ID NCT07342179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 60 multiple myeloma patients who are about to receive CAR-T cell therapy. Researchers will measure a specific immune marker (TCF-1) in the blood before treatment and track how long the modified CAR-T cells last afterward. The goal is to find clues that predict which patients will have the best response, without giving any new treatment or changing standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu de Poitiers
RECRUITINGPoitiers, 86000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- MRI scans may reveal hidden clues to myeloma relapse risk
- Can a dual immunotherapy erase hidden myeloma cells?
- Does CAR-T therapy affect the brain? a study investigates
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Can a closer look at bone complications in multiple myeloma improve rehabilitation?
- Gene-Guided Chemo-Free strategy targets AL amyloidosis